Patents by Inventor Michael Goggins

Michael Goggins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200255903
    Abstract: Described are telomere fusion assays to detect dysplasia in subjects using nested primers. The methods of the present invention are able to detect dysplasia in subjects with intraductal papillary mucinous neoplasma (IPMNs), for example.
    Type: Application
    Filed: September 24, 2018
    Publication date: August 13, 2020
    Inventors: Michael Goggins, Tatsuo Hata
  • Patent number: 9315868
    Abstract: The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: April 19, 2016
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein, Manuel Hidalgo, Victor E. Velculescu
  • Publication number: 20160032406
    Abstract: The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 4, 2016
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein, Manuel Hidalgo, Victor Velculescu
  • Patent number: 9115403
    Abstract: The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 25, 2015
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein, Manuel Hidalgo, Victor E. Velculescu
  • Publication number: 20120115735
    Abstract: There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples.
    Type: Application
    Filed: September 3, 2009
    Publication date: May 10, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein
  • Publication number: 20120034318
    Abstract: The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.
    Type: Application
    Filed: March 5, 2010
    Publication date: February 9, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein, Manuel Hidalgo, Victor E. Velculescu
  • Publication number: 20070202499
    Abstract: The present invention includes methods diagnosising of cancer by analysis of a patient sample, particularly for the presence of a methylated SPARC nucleic acid molecule, and particularly for the diagnosis of pancreatic cancer. The invention also includes therapeutic methods for treating cancers by administering to cancers patients therapeutically effective amounts of demethylating agents.
    Type: Application
    Filed: June 24, 2004
    Publication date: August 30, 2007
    Inventors: Michael Goggins, Sato Norihiro
  • Publication number: 20070015156
    Abstract: The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject.
    Type: Application
    Filed: March 17, 2004
    Publication date: January 18, 2007
    Inventor: Michael Goggins
  • Publication number: 20050095611
    Abstract: The present invention relates to a method of qualifying pancreatic cancer status in a subject comprising: (a) measuring at least one of the disclosed biomarkers in a sample from the subject and (b) correlating the measurement with pancreatic cancer status. The invention further relates to kits for qualifying pancreatic cancer status in a subject.
    Type: Application
    Filed: April 30, 2004
    Publication date: May 5, 2005
    Inventors: Daniel Chan, Zhen Zhang, Jens Koopmann, Michael Goggins, C. White, Eric Fung, Xiao-Ying Meng
  • Publication number: 20050069924
    Abstract: The present invention provides a method for detecting a cellular proliferative disorder in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having said cellular proliferative, thereby detecting a cellular proliferative disorder in the subject.
    Type: Application
    Filed: July 8, 2004
    Publication date: March 31, 2005
    Inventors: Michael Goggins, Takashi Ueki